Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer.

Abstract:

BACKGROUND:DS60 is a novel buoyant density solution, whose density has been adjusted to enrich PBSC from subjects who have been mobilized with cytokines alone, or cytokines plus chemotherapy. This report describes the use of BDS60 to enrich autologous PBSC that were used for hematological reconstitution after myeloablative chemotherapy in women with breast cancer. METHODS:Fifty-one consecutive patients with high-risk Stage II or III breast cancer or chemotherapy-sensitive Stage IV breast cancer were enrolled. Forty-seven completed treatment and were evaluable. After mobilization with cyclophosphamide (4.0 g/m(2) i.v. once) and filgrastim (10 microg/kg/day), the patients underwent leukapheresis and the products were enriched with BDS60 using the DACS300 Kit. Myeloablative chemotherapy, given on Day -5 through Day -2, consisted of cyclophosphamide (1.5 g/m(2)/day), thiotepa (150 mg/m(2)/day) and carboplatin (200 mg/m(2)/day). RESULTS:Forty-one patients underwent a single leukapheresis procedure to achieve the target number of BDS60-enriched CD34+ cells for transplantation (> or = 2 x 10(6)/kg). Five of the other six patients had less than the target number of cells in the leukapheresis product and thus required 2-4 leukapheresis procedures. Median cell recovery was 76.8% for CD34+ cells, 39.1% for nucleated cells, and 17.7% for platelets. Erythrocyte contamination of the final product was negligible. The median time to sustained neutrophil count > 500/mm(3) was 9 days (range: 8-12) and the median time to platelet count > 20 000/mm(3), without transfusion support, was also 9 days (range: 6-15). There were no late graft failures. Infusion-related adverse events were mild and no adverse events were attributed to the use of BDS60 to enrich CD34+ cells. DISCUSSION:BDS60 is an effective, rapid method for enrichment of CD34+ cells by buoyant density centrifugation and the resulting cell product is safe and effective for engraftment after myeloablative therapy.

journal_name

Cytotherapy

journal_title

Cytotherapy

authors

Laport GG,Valone FH,Zimmerman TM,Grinblatt DL,Van Vlasselaer P,Still BJ,Williams SF

doi

10.1080/146532400539134

keywords:

subject

Has Abstract

pub_date

2000-01-01 00:00:00

pages

179-85

issue

3

eissn

1465-3249

issn

1477-2566

pii

S1465-3249(00)70928-5

journal_volume

2

pub_type

临床试验,杂志文章
  • Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway.

    abstract:BACKGROUND AIMS:Imatinib (IM), a tyrosine kinase inhibitor targeting the BCR-ABL oncoprotein, remains a major therapeutic strategy for patients with chronic myelogenous leukemia (CML). However, IM resistance is still a challenge in the treatment of CML. Recently, it was reported that exosomes (Exo) were involved in dru...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2017.11.006

    authors: Liu Y,Song B,Wei Y,Chen F,Chi Y,Fan H,Liu N,Li Z,Han Z,Ma F

    更新日期:2018-02-01 00:00:00

  • Building blocks for institutional preparation of CTL019 delivery.

    abstract::Chimeric antigen receptor (CAR) T-cell therapy is an investigational immunocellular therapy that reprograms a patient's cytotoxic T cells to engage and eliminate malignant cells. CAR T-cell therapies targeting the CD19 antigen have demonstrated high efficacy in clinical trials for patients with B-cell malignancies and...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1016/j.jcyt.2017.06.001

    authors: McGuirk J,Waller EK,Qayed M,Abhyankar S,Ericson S,Holman P,Keir C,Myers GD

    更新日期:2017-09-01 00:00:00

  • Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.

    abstract:BACKGROUND AIMS:The aim of this study was to evaluate the efficacy and safety of cytokine-induced killer (CIK) cell therapy for solid carcinomas. METHODS:We performed a computerized search of phase II/III clinical trial databases of CIK cell-based therapy using a combination of the terms 'cytokine-induced killer cells...

    journal_title:Cytotherapy

    pub_type: 杂志文章,meta分析,评审

    doi:10.3109/14653249.2011.649185

    authors: Ma Y,Zhang Z,Tang L,Xu YC,Xie ZM,Gu XF,Wang HX

    更新日期:2012-04-01 00:00:00

  • Comparative analysis of the immunomodulatory capacities of human bone marrow- and adipose tissue-derived mesenchymal stromal cells from the same donor.

    abstract:BACKGROUND AIMS:The immunomodulatory properties of mesenchymal stromal cells (MSCs), together with their tissue regenerative potential, make them interesting candidates for clinical application. METHODS:In the current study, we analyzed the in vitro immunomodulatory effects of MSCs derived from bone marrow (BM-MSCs) a...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2016.07.006

    authors: Valencia J,Blanco B,Yáñez R,Vázquez M,Herrero Sánchez C,Fernández-García M,Rodríguez Serrano C,Pescador D,Blanco JF,Hernando-Rodríguez M,Sánchez-Guijo F,Lamana ML,Segovia JC,Vicente Á,Del Cañizo C,Zapata AG

    更新日期:2016-10-01 00:00:00

  • Transiently redirected T cells for adoptive transfer.

    abstract:BACKGROUND AIMS:T cells can be redirected to reject cancer by retroviral transduction with a chimeric antigen receptor (CAR) or by administration of a bispecific T cell engager (BiTE). We demonstrate that transfection of T cells with messenger (m) RNA coding for CAR is an alternative strategy. METHODS:We describe the ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653249.2010.542461

    authors: Almåsbak H,Rian E,Hoel HJ,Pulè M,Wälchli S,Kvalheim G,Gaudernack G,Rasmussen AM

    更新日期:2011-05-01 00:00:00

  • Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience.

    abstract:BACKGROUND AIMS:Corticosteroids are the standard first-line treatment for acute graft-versus-host disease (aGVHD), but they are associated with many complications, and less than half of patients have a sustained response. METHODS:To improve outcomes, we performed a retrospective study to analyze the efficacy of the ad...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2020.03.003

    authors: Sestili S,Eder S,Belhocine R,Dulery R,Battipaglia G,Brissot E,Mediavilla C,Banet A,van de Wyngaert Z,Paviglianiti A,Ledraa T,Bonin A,Mohty M,Malard F

    更新日期:2020-08-01 00:00:00

  • Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA/BCL-2 expression.

    abstract:BACKGROUND:Multiple myeloma (MM) is a hematologic cancer caused by the abnormal expansion of plasma cells, but the exact mechanism underlying MM development is not completely known. Recently, multiple long noncoding RNAs (lncRNAs) were implicated in the regulation of MM development. METHODS:Samples from patients with ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2018.10.006

    authors: Deng M,Yuan H,Liu S,Hu Z,Xiao H

    更新日期:2019-01-01 00:00:00

  • CD133 immunomagnetic separation: effectiveness of the method for CD133(+) isolation from umbilical cord blood.

    abstract:BACKGROUND AIMS:Umbilical cord blood (UCB) is a rich source of stem cells, the characterization and isolation of which requires specific stem cell markers and reliable and reproducible protocols. METHODS:We assessed CD133 isolation in 39 UCB samples, using a commercial immunomagnetic cell-sorting protocol, and, becaus...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653249.2012.663487

    authors: Pelagiadis I,Relakis K,Kalmanti L,Dimitriou H

    更新日期:2012-07-01 00:00:00

  • Genomic and functional comparison of mesenchymal stromal cells prepared using two isolation methods.

    abstract:BACKGROUND AIMS:Mesenchymal stromal cells (MSCs) have been applied to patients in cell therapy for various diseases. Recently, we introduced a novel MSC separation filter device which could yield approximately 2.5-fold more MSCs from bone marrow in a closed system compared with the conventional open density gradient ce...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2014.10.013

    authors: Otsuru S,Hofmann TJ,Raman P,Olson TS,Guess AJ,Dominici M,Horwitz EM

    更新日期:2015-03-01 00:00:00

  • Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential.

    abstract:BACKGROUND:BM mesenchymal stem cells (MSC) have the capacity for renewal and the potential to differentiate into multiple tissues. In this study, we compared different enrichment methods to obtain MSC from BM. METHODS:Three different methods were compared with a view to obtaining MSC more rapidly from BM: negative sel...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/14653240410004943

    authors: Tondreau T,Lagneaux L,Dejeneffe M,Delforge A,Massy M,Mortier C,Bron D

    更新日期:2004-01-01 00:00:00

  • Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-γ and tumor necrosis factor-α stimulation.

    abstract:BACKGROUND AIMS:Mesenchymal stromal cells (MSCs) suppress T-cell proliferation, especially after activation with inflammatory cytokines. We compared the dynamic action of unprimed and interferon (IFN)-γ plus tumor necrosis factor (TNF)-α-pretreated human bone marrow-derived MSCs on resting or activated T cells. METHOD...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2013.11.008

    authors: Cuerquis J,Romieu-Mourez R,François M,Routy JP,Young YK,Zhao J,Eliopoulos N

    更新日期:2014-02-01 00:00:00

  • Stem cell comparison: what can we learn clinically from unrelated cord blood transplantation as an alternative stem cell source?

    abstract::Allogeneic hematopoietic cell transplantation (HCT) is an important therapeutic option for a variety of malignant and non-malignant disorders (NMD). The use of umbilical cord blood transplantation (UCBT) has made HCT available to many more patients. The increased level of human leukocyte antigen disparity that can be ...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1016/j.jcyt.2015.03.003

    authors: Milano F,Boelens JJ

    更新日期:2015-06-01 00:00:00

  • Neural stem cells transplanted to the subretinal space of rd1 mice delay retinal degeneration by suppressing microglia activation.

    abstract:BACKGROUND AIMS:Retinal degeneration (RD) is an inherited eye disease characterized by irreversible photoreceptor loss. Conventionally, the activation of the resident microglia is secondary to the disease. Stem cell-based therapy has recently made rapid progress in treating RD. Although it has been demonstrated that th...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2016.03.001

    authors: Li Z,Zeng Y,Chen X,Li Q,Wu W,Xue L,Xu H,Yin ZQ

    更新日期:2016-06-01 00:00:00

  • Selective depletion strategies in allogeneic stem cell transplantation.

    abstract::Despite improved prophylaxis and treatment, GvHD remains a major limitation to optimal allogeneic stem cell transplantation. Ex vivo selective depletion (SD) is a strategy to prevent GvHD, in which host-reactive donor lymphocytes are selectively eliminated from a PBSC allograft while useful donor immune function is pr...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14653240510018172

    authors: Mielke S,Solomon SR,Barrett AJ

    更新日期:2005-01-01 00:00:00

  • New allergies after cord blood transplantation.

    abstract:BACKGROUND AIMS:Umbilical cord blood transplantation (CBT) is an effective treatment for benign and malignant diseases. Late effects of CBT are not well described in the literature. In the present study, we present our experience of new-onset allergies in long-term survivors after CBT. METHODS:After an initial patient...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2013.05.018

    authors: Vaughan LA,Vu M,Sengsayadeth S,Lucid C,Clifton C,McCarty K,Hagaman D,Domm J,Kassim A,Chinratanalab W,Goodman S,Greer J,Frangoul H,Engelhardt BG,Jagasia M,Savani BN

    更新日期:2013-10-01 00:00:00

  • Development of standardized cell culture conditions for tumor cells with potential clinical application.

    abstract:BACKGROUND:Tumor cell lines have enormous value for the study of different aspects of cancer biology and have also recently gained great importance in autologous cell-based anti-tumor therapies. However, the use of these cells is still limited because in vitro growth is hampered by suboptimal culture conditions and cur...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/14653240701385836

    authors: Stadler G,Wieser M,Steindl F,Grillari J,Katinger H,Pfragner R,Voglauer R

    更新日期:2007-01-01 00:00:00

  • Intravenous infusion of adipose-derived stem/stromal cells improves functional recovery of rats with spinal cord injury.

    abstract:BACKGROUND AIMS:Adipose tissue has therapeutic potential for spinal cord injury (SCI) because it contains multipotent cells known as adipose-derived stem/stromal cells (ASCs). In this study, we attempted intravenous ASC transplantation in rats with SCI to examine the effect on functional recovery. METHODS:ASCs (2.5 × ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2017.04.002

    authors: Ohta Y,Hamaguchi A,Ootaki M,Watanabe M,Takeba Y,Iiri T,Matsumoto N,Takenaga M

    更新日期:2017-07-01 00:00:00

  • Large-scale Ficoll gradient separations using a commercially available, effectively closed, system.

    abstract:BACKGROUND AIMS:Multiple cell-therapy products require density separation as a part of manufacturing. The traditional method for Ficoll separation, layering cell suspensions over Ficoll in tubes, followed by centrifugation and collection of cells from the interface, is too cumbersome and poses too high a risk of contam...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653240903479663

    authors: Janssen WE,Ribickas A,Meyer LV,Smilee RC

    更新日期:2010-05-01 00:00:00

  • Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy.

    abstract:BACKGROUND:There is growing interest in the use of dendritic cells (DCs) for treatment of malignancy and infectious disease. Our goal was to develop a clinical scale method to prepare autologous DCs for cancer clinical trials. METHODS:PBMC were collected from normal donors or cancer patients by automated leukapheresis...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/146532401753156377

    authors: Wong EC,Maher VE,Hines K,Lee J,Carter CS,Goletz T,Kopp W,Mackall CL,Berzofsky J,Read EJ

    更新日期:2001-01-01 00:00:00

  • Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.

    abstract::Targeted adoptive immunotherapy with engineered T cells is a promising treatment for refractory hematologic malignancies. However, many patients achieving early complete remissions ultimately relapse. Immunosuppressive ligands are expressed on tumor and supportive cells in the tumor microenvironment (TME). When activa...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2018.07.005

    authors: Zolov SN,Rietberg SP,Bonifant CL

    更新日期:2018-10-01 00:00:00

  • Ex vivo immunological evaluation of stable mixed chimeric patients after matched related donor allogeneic transplantation in sickle cell disease.

    abstract:BACKGROUND AIMS:Allogeneic hematopoietic stem cell transplantation is curative for sickle cell disease, and the use of matched related donors, non-myeloablative conditioning and sirolimus immunosuppression results in stable mixed chimerism without graft-versus-host disease (GVHD). However, the time to terminate sirolim...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2019.10.003

    authors: Raines LN,Hsieh MM,Nassehi T,Drysdale CM,Tisdale JF,Uchida N

    更新日期:2019-12-01 00:00:00

  • Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca(2+) transport ATPase 2 regulation.

    abstract:BACKGROUND AIMS:It is important to improve the migratory ability of dendritic cells (DCs) and to increase DC potency for successful DC-based cancer immunotherapy. The intracellular Ca(2+) signaling pathway has an important role on the regulation of DC migration. Our preliminary studies revealed that sarco/endoplasmic r...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2015.06.002

    authors: Choi NR,Lee HJ,Jung SH,Hong CY,Vo MC,Hoang MD,Kim HJ,Lee JJ

    更新日期:2015-10-01 00:00:00

  • In vitro expression of erythropoietin by transfected human mesenchymal stromal cells.

    abstract:BACKGROUND:Mesenchymal stromal cells (MSC) are pluripotent progenitor cells that can be found in human bone marrow (BM). These cells have low immunogenicity and could suppress alloreactive T-cell responses. In the current study, MSC were tested for their capacity to carry and deliver the erythropoietin (EPO) gene in vi...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1080/14653240701816996

    authors: Mok PL,Cheong SK,Leong CF,Othman A

    更新日期:2008-01-01 00:00:00

  • Species variation in the spontaneous calcification of bone marrow-derived mesenchymal stem cells.

    abstract::Bone marrow-derived mesenchymal stem cells (BM-MSCs) hold great promise for tissue regeneration. With increasing numbers of clinical trials, the safety of BM-MSCs attracts great interest. Previously, we determined that rat BM-MSCs possessed spontaneous calcification without osteogenic induction after continuous cultur...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2012.11.011

    authors: Huang YZ,Cai JQ,Lv FJ,Xie HL,Yang ZM,Huang YC,Deng L

    更新日期:2013-03-01 00:00:00

  • International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.

    abstract::Mesenchymal stromal cells (MSCs) as a pharmaceutical for ailments characterized by pathogenic autoimmune, alloimmune and inflammatory processes now cover the spectrum of early- to late-phase clinical trials in both industry and academic sponsored studies. There is a broad consensus that despite different tissue sourci...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2015.11.008

    authors: Galipeau J,Krampera M,Barrett J,Dazzi F,Deans RJ,DeBruijn J,Dominici M,Fibbe WE,Gee AP,Gimble JM,Hematti P,Koh MB,LeBlanc K,Martin I,McNiece IK,Mendicino M,Oh S,Ortiz L,Phinney DG,Planat V,Shi Y,Stroncek DF,Vi

    更新日期:2016-02-01 00:00:00

  • Human umbilical cord mesenchymal stromal cells mitigate chemotherapy-associated tissue injury in a pre-clinical mouse model.

    abstract:BACKGROUND AIMS:Mesenchymal stromal cells (MSC) have been shown to be a promising candidate for tissue regeneration and cancer therapy. However, their therapeutic potential against chemotherapy-induced side-effects remains unclear. METHODS:We treated murine Lewis lung carcinoma (LLC) and xenograft human colon tumors w...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653249.2011.646044

    authors: Di GH,Jiang S,Li FQ,Sun JZ,Wu CT,Hu X,Duan HF

    更新日期:2012-04-01 00:00:00

  • Neonatal sex and weight influence CD34(+) cell concentration in umbilical cord blood but not stromal cell-derived factor 1-3'A polymorphism.

    abstract:BACKGROUND:Umbilical cord blood (UCB) has been used as an alternative source of donor hematopoietic stem cells for hematologic transplant setting over the past decade. This study attempted to evaluate potential predictors of cord blood quality. METHODS:A total of 750 UCB samples were studied (male, n = 365; female, n ...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2014.09.002

    authors: Bijou F,Ivanovic Z,Fizet D,Dazey B,Boiron JM,Lafarge X

    更新日期:2015-01-01 00:00:00

  • Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy.

    abstract::Mesenchymal stromal cells (MSCs) are multipotent cells derived from various tissues that can differentiate into several cell types. MSCs are able to modulate the response of immune cells of the innate and adaptive immune system. Because of these multimodal properties, the potential use of MSCs for immunotherapies is c...

    journal_title:Cytotherapy

    pub_type: 杂志文章,评审

    doi:10.1016/j.jcyt.2017.03.076

    authors: de Wolf C,van de Bovenkamp M,Hoefnagel M

    更新日期:2017-07-01 00:00:00

  • Activation of bone marrow-derived mesenchymal stromal cells-a new mechanism of defocused low-energy shock wave in regenerative medicine.

    abstract:BACKGROUND AIMS:Defocused low-energy shock wave (DLSW) therapy has shown effectiveness in regenerative medicine. The mechanism of action was mainly focused on the pathophysiological improvement at the wound tissues. In this study, the activation of stem cells treated by DLSW was first examined as an important pathway d...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.1016/j.jcyt.2013.08.012

    authors: Zhao Y,Wang J,Wang M,Sun P,Chen J,Jin X,Zhang H

    更新日期:2013-12-01 00:00:00

  • Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.

    abstract:BACKGROUND AIMS:Human gamma-delta (γδ) T cells are potent effector lymphocytes of innate immunity involved in anti-tumor immune surveillance. However, the Vδ1 γδ T-cell subset targeting multiple myeloma (MM) has not previously been investigated. METHODS:Vδ1 T cells were purified from peripheral blood mononuclear cells...

    journal_title:Cytotherapy

    pub_type: 杂志文章

    doi:10.3109/14653249.2012.700766

    authors: Knight A,Mackinnon S,Lowdell MW

    更新日期:2012-10-01 00:00:00